Law firm investigates Omeros after stock drops on negative EMA drug approval opinions
Alpha Vantage · Pluang · · AI-summarised by FinFlash
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud following two significant stock price drops. These drops occurred after the European Medicines Agency (EMA) issued negative opinions on Omeros's drug narsoplimab, leading to rejections of its marketing authorization application. The investigation could impact investor confidence and legal outcomes for Omeros.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.